




PHARMACEUTICAL 2019

Dova Pharmaceuticals Inc.
Rank 197 of 363





PHARMACEUTICAL 2019

Dova Pharmaceuticals Inc.
Rank 197 of 363

The relative strengths and weaknesses of Dova Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dova Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Dova Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 80%, being 43% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	111,807
Cost of Goods Sold	1,180
Intangible Assets	0
Liabilities, Current	19,497
Liabilities, Non-Current	2,373
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	13,941
Other Net Income	-1,232
Other Revenues	10,355
Property and Equipment	362
Research and Development	18,304
Selling, General and Administrative Expense	61,921

Output Variable	Value in 1000 USD
Assets	112,169
Liabilities	35,811
Expenses	81,405
Revenues	10,355
Stockholders Equity	76,358
Net Income	-72,282
Comprehensive Net Income	-72,282
Economic Capital Ratio	80%